Dyax Corp. To Present at the Lazard Capital Markets Healthcare Conference
Posted on: Tuesday, 20 November 2007, 09:01 CST
Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, will present at the 4th Annual Lazard Capital Markets Healthcare Conference, being held November 27-28 at the New York Place Hotel in New York City. Mr. Blair will present a corporate progress report, including an update on the Company's clinical development programs. The Dyax Corp. presentation is scheduled for Tuesday, November 27 at 4:30 PM (ET).
The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The 25-minute presentation will also be available on the Dyax website for a limited period of time following the conference.
About Dyax
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.
Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A second Phase 3 trial, known as EDEMA4, is currently being conducted under a Special Protocol Assessment (SPA). DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.
Additionally, Dyax has completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. A Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures, is ongoing.
Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com.
Source: Business Wire
Related Articles
- Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
- TorreyPines Initiates Phase I Trial of Pain Compound
- Genaera Corporation Begins Dosing in Phase 1 Trial of Obesity Compound Trodusquemine
- IL-1 Trap Phase 3 Trial Data Presented at Annual Meeting of American Academy of Allergy, Asthma and Immunology (AAAAI)
- EPIX Pharmaceuticals Announces Top-Line Results From Phase 3 Trial of PRX-00023 in Generalized Anxiety Disorder; Investor Conference Call Scheduled for September 22, 2006 at 8:30AM Eastern Time
- Nereus Begins Phase I Trial of Anticancer Compound
- Additional Data From Phase I Trials of Exelixis Compounds XL647, XL880 and XL999 to Be Reported at ASCO
- Inotek Pharmaceuticals Enters Phase 1 Trials With Its Second Clinical Compound
- Exelixis Initiates Phase I Trial for Anticancer Compound XL880
- Inotek Pharmaceuticals Announces Commencement of Enrollment in Phase 2 Trial on Lead Compound
 |
 |
User Comments (0)
RSS Feeds